Columbia Laboratories Inc.

Mr. Mills joined Columbia in May 2001 as senior vice president, operations. He was named chief operating officer in September 2003, at which time he assumed full responsibility for R&D, including the preterm study. In January 2006, Mr. Mills was appointed president and was elected to the Company’s Board of Directors. Prior to joining Columbia, Mr. Mills served five years as Senior Vice President, Manufacturing Operations, at Watson Pharmaceuticals. During his 30-year career in the pharmaceutical industry he also served as Vice President, Operations, at Alpharma, Inc. and held various positions with Aventis, SA, including Director-Plant Operations. Mr. Mills holds a B.S. from Grove City College.

Mr. Meer has served as Senior Vice President, Chief Financial Officer and Treasurer since December 2006. He has over 35 years of financial experience in both privately-held and publicly-traded companies, of which over 15 years are in the life sciences industry. He most recently served from 2004 to 2006 as Senior Vice President, Chief Financial Officer, Secretary and Treasurer of Pharmos Corporation, a biotechnology company, prior to which he was a consultant from 2001 to 2004 to pharmaceutical and biotech companies providing strategic and financial advice. Mr. Meer previously served eight years as Vice President and Treasurer of Schein Pharmaceutical, Inc., where he was responsible for capital formation, including a successful IPO, strategic planning and investor relations. He also held senior financial positions with public companies including EnviroSource, Inc., John Labatt Ltd. and General Host Corporation. Mr. Meer holds an M.B.A. degree from Pace University and a B.A. degree on economics from Rutgers College.

Mr. McGrane served as Vice President, General Counsel and Secretary since January 2002 and was promoted to Senior Vice President in January 2006. He joined Columbia from The Liposome Company, Inc., a biotechnology company, where he served as Vice President, General Counsel and Secretary, prior to which he was Vice President, General Counsel and Secretary to Novartis Consumer Health, Inc. Previously, Mr. McGrane held various positions with Novartis Pharmaceuticals Corporation, including Associate General Counsel, and was Regulatory Counsel to the U.S. Food and Drug Administration. Mr. McGrane received his J.D. degree from Georgetown University and his B.A. degree from Cornell College. He is a member of the New Jersey bar.

Dr. Creasy joined Columbia Laboratories as Vice President, Clinical Research and Development in November 2003. Before joining the Company, he was responsible for clinical development and management of reproductive health products in his more than 16 years with Johnson & Johnson. He was a faculty member of Penn State's Hershey Medical Center prior to starting his pharmaceutical career. A trained Obstetrician and Gynecologist, Dr. Creasy is a graduate of the Pennsylvania State University School of Medicine and a Fellow of the American College of Obstetricians and Gynecologists.

In 1996, Ing. Larios began working the predecessor companies that led to ETI's formation, joining their U.S. counterparts as founders of ETI in April of 1999. Since 1977, Ing. Larios has owned and operated Aguilas de Occidente, S.A. de C.V., a large transportation company servicing domestic and international clients throughout Mexico. Evolving over decades of close friendship, Ing. Larios was recently asked by President Vicente Fox to serve as Fox's personal advisor on economic issues for Mexico. Ing. Larios participated in the personnel analysis that led to the new selections for Fox's new Cabinet and enjoys personal relationships with many of those new appointees, including Victor Lichtinger, the Minister of the Environment; Ernesto Martens, the Minister of Energy; and Raul Munoz Leos, the new chief executive of PEMEX. One of the most well-respected business advisors in the history of Mexico, Hector served, from 1995-97, as the President of Consejo Coordinador Empresarial (CCE), a consortium of private sector business and industrial interests that functions as a master chamber of commerce for the entire nation, exerting the highest level of influence on Mexico's economy and government. From 1966 to 1978, he was the President of Construcciones y Servicios Industriales, a Mexican construction company. His highly distinguished career includes positions such as President of the Pan-American Institute for Senior Business Management (IPD), President of the Patrimonial Confederation of the Republic of Mexico (CPM), founding commission member of the Economic Recovery Commission for Mexico (ARE), and many other celebrated organizations. He still serves as an advisor to CCE, IPD, CPM, ARE, the Red Cross, Pan-American University, the Engineering Faculty for UNAM University, the National Transportation Union, Columbia Laboratories, United American Financial Services (Houston, TX), Grupo Dina, and many other private and public enterprises. Hector graduated from UNAM University in Mexico City in 1966 with a double major in mechanical and electrical engineering.

Dr. Nelson is the medical director of CFHC. She also serves as a Professor of Obstetrics and Gynecology at the UCLA School of Medicine and is a full-time faculty member in the gynecology department at the Harbor-UCLA Medical Center where she directs the Women's Health Care Clinic (WHCC) and the largest women's health care nurse practitioner training program in the country. In addition, she conducts the contraceptive training of OB-GYN and family practice residents at Harbor-UCLA, and the internal medicine residents at St. Mary's Hospital in Long Beach. She also supervises the residents in the Abnormal Cytology Clinic.

Mr. Campbell has been a director of Columbia since December 2008 and is a Portfolio Manager and Senior Analyst for Dorset Management Corporation since January 2000 and a Director of Knott Partners Management, LLC (investment advisors) since 2004. Mr. Campbell founded Windsor Partners, L.P. (investment advisors) in 1986. He was Principal and Managing Director of Berg Capital Corporation, a registered investment advisor, from 1984 through 1985, and also served as General Partner of Chelsea Partners, a private investment partnership, during that time. Mr. Campbell was a Vice President at the First Boston Corporation from 1975 through 1984, and from 1969 until 1975 was at McLeod, Young, Weir, Ltd. (investment advisors) in Canada and was appointed a Vice President in 1973. He is currently a director of Magna Entertainment (pari-mutuel wagering).

Array

Mr. Condella has been a director of Columbia since March 2009. He was Chief Executive Officer of SkyePharma plc (pharmaceuticals) from March 2006 to September 2008, President of Europe and Managing Director, UK, at IVAX Corporation (pharmaceuticals) from 2002 to February 2006, and President and Chief Executive Officer of Faulding Pharmaceuticals, from 2000 to 2001. Previously he was Vice-President of Specialty Care Products at Hoffman-La Roche (pharmaceuticals) and Vice-President and General Manager of the Lederle unit of American Home Products (pharmaceuticals). Mr. Condella is a non-executive director of SkyePharma plc and Fulcrum Pharma plc (pharmaceuticals)